Is MEDIF or EQR a better dividend investment in 2026?

MEDIF currently yields 4345.46% with a 5% 5-year dividend growth rate. EQR yields 5.87% with 5% growth. The better choice depends on your goal: MEDIF offers higher current income.

What is the dividend yield difference between MEDIF and EQR?

MEDIF has a forward dividend yield of 4345.46% ($2.00/share annually). EQR yields 5.87% ($3.47/share annually). The yield gap is 4339.59 percentage points.

Home › Compare › MEDIF vs EQR

MEDIF vs EQR: Dividend Comparison 2026

MEDIF yields 4345.46% · EQR yields 5.87%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 MEDIF wins by $15969693446288.74M in total portfolio value

INVESTMENT

TIME HORIZON10 years

MEDIF

● Live price

4345.46%

Share price

$0.05

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$15969693446288.79M

Annual income

$15,278,069,441,942,714,000.00

Full MEDIF calculator →

EQR

● Live price

5.87%

Share price

$59.15

Annual div

$3.47

5Y div CAGR

15.8%

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$47.8K

Annual income

$5,475.61

Full EQR calculator →

Portfolio growth — MEDIF vs EQR

📍 MEDIF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	MEDIF	EQR
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, MEDIF + EQR cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

MEDIF pays

EQR pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MEDIF

Annual income on $10K today (after 15% tax)

$369,364.48/yr

After 10yr DRIP, annual income (after tax)

$12,986,359,025,651,306,000.00/yr

EQR

Annual income on $10K today (after 15% tax)

$499.01/yr

After 10yr DRIP, annual income (after tax)

$4,654.27/yr

At 15% tax rate, MEDIF beats the other by $12,986,359,025,651,302,000.00/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MEDIF + EQR for your $10,000?

MEDIF: 50%EQR: 50%

100% EQR50/50100% MEDIF

Portfolio after 10yr

$7984846723144.42M

Annual income

$7,639,034,720,971,360,000.00/yr

Blended yield

95.67%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

MEDIF

No analyst data

Altman Z

-2.9

Piotroski

2/9

EQR

Analyst Ratings

Buy

Hold

Sell

Consensus: Hold

Price Target

$70.35

+18.9% upside vs current

Range: $63.00 — $78.50

Altman Z

1.8

Piotroski

7/9

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MEDIF buys

EQR buys

No recent congressional trades found for MEDIF or EQR in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricMEDIFEQR

Forward yield	4345.46% ✓	5.87%
Annual dividend / share	$2.00	$3.47 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	15.8% ✓
Portfolio after 10y	$15969693446288.79M ✓	$47.8K
Annual income after 10y	$15,278,069,441,942,714,000.00 ✓	$5,475.61
Total dividends collected	$15922667488789.34M ✓	$23.0K
Payment frequency	quarterly	quarterly
Sector	Stock	REIT

Year-by-year: MEDIF vs EQR ($10,000, DRIP)

Year	MEDIF Portfolio	MEDIF Income/yr	EQR Portfolio	EQR Income/yr	Gap
1← crossover	$445,246	$434,546.44	$11,380	$679.82	+$433.9K → MEDIF
2	$18,558,681	$18,082,267.04	$13,014	$837.25	+$18.55M → MEDIF
3	$724,251,944	$704,394,155.22	$14,961	$1,036.20	+$724.24M → MEDIF
4	$26,465,566,588	$25,690,617,008.13	$17,297	$1,289.22	+$26465.55M → MEDIF
5	$905,687,152,836	$877,368,996,586.58	$20,121	$1,613.15	+$905687.13M → MEDIF
6	$29,029,592,495,582	$28,060,507,242,048.22	$23,561	$2,030.84	+$29029592.47M → MEDIF
7	$871,632,797,918,927	$840,571,133,948,653.80	$27,783	$2,573.54	+$871632797.89M → MEDIF
8	$24,520,223,407,609,444	$23,587,576,313,836,190.00	$33,013	$3,284.39	+$24520223407.58M → MEDIF
9	$646,377,574,155,211,500	$620,140,935,109,069,400.00	$39,547	$4,223.51	+$646377574155.17M → MEDIF
10	$15,969,693,446,288,792,000	$15,278,069,441,942,714,000.00	$47,791	$5,475.61	+$15969693446288.74M → MEDIF

MEDIF vs EQR: Complete Analysis 2026

MEDIF — Stock

MediPharm Labs Corp., a pharmaceutical company, produces and sells pharmaceutical-quality cannabis oil and concentrates, and advanced derivative products in Canada, Australia, Germany, and internationally. It formulates, processes, packages, and distributes cannabis extracts and advanced cannabinoid-based products. The company also provides GMP flower sourcing, packaging, and distribution services. MediPharm Labs Corp. was founded in 2015 and is headquartered in Barrie, Canada.

Full MEDIF Calculator →

EQR — REIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →

📬

Get this MEDIF vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MEDIF vs SCHD MEDIF vs JEPI MEDIF vs O MEDIF vs KO MEDIF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.